Search results for "coagulants"

showing 10 items of 248 documents

Periodontal and biochemical bone metabolism assessment on a chronic oral anticoagulation population treated with dicoumarins

2016

Background The aim is to evaluate periodontal alteration and biochemical markers associated with bone turnover in chronic oral with dicoumarins anticoagulant treatment patients. Material and Methods 80 patients treated with oral anticoagulants were divided into 2 cohort: Group A (n=36) 6 month to 1 year with anticoagulant treatment and Group B (n=44) > 2 years with anticoagulant treatment. Clinical evaluation included: Clinical attachment level (CAL), plaque index (PI) and gingival index (GI). Analytically biochemical parameters of bone remodeling (calcium and phosphorus), formation (total acid phosphatase, alkaline phosphatase and osteocalcin) and resorption (tartrate-resistant acid phosph…

MalePeriodontiumDicumarolmedicine.medical_specialtyPopulationAdministration OralDentistryGastroenterologyGroup ABone and BonesGroup BBone remodeling03 medical and health sciencesGingivitis0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineeducationGeneral DentistryAgededucation.field_of_studybiologybusiness.industryResearchAcid phosphataseAnticoagulants030206 dentistry:CIENCIAS MÉDICAS [UNESCO]OtorhinolaryngologyUNESCO::CIENCIAS MÉDICASOsteocalcinbiology.proteinAlkaline phosphataseFemaleSurgeryOral Surgerymedicine.symptombusinessBiomarkers
researchProduct

Antibacterial and anticoagulant activities of coumarins isolated from the flowers of Magydaris tomentosa.

2006

The phytochemical investigation of the acetone and methanol extracts of the flowers of Magydaris tomentosa (Desf.) DC afforded six known coumarins as well as (+)-meranzin hydrate (7), not previously reported as a natural product. The antibacterial activity of umbelliprenin (1), osthol (2), imperatorin (3), citropten (4) and (+)-meranzin hydrate (7) was tested against Gram-positive and Gram-negative bacteria. All coumarins (1-7) isolated in this study inhibited growth of all bacterial strains tested (MIC between 16 and 256 microg/mL), the most active being imperatorin (3) (MICs between 32 and 128 microg/mL) and citropten (4) (MICs between 16 and 256 microg/mL). The anticoagulant activity of …

MalePharmaceutical ScienceCitroptenFlowersMicrobial Sensitivity TestsPharmacognosyAnalytical Chemistrychemistry.chemical_compoundCoumarinsDrug DiscoveryOrganic chemistryAnimalsRats WistarAntibacterial agentPharmacologyApiaceaebiologyTraditional medicineImperatorinOrganic ChemistryAnticoagulantsbiology.organism_classificationAnti-Bacterial AgentsRatsComplementary and alternative medicinechemistryPhytochemicalMolecular MedicineAntibacterial activityOstholApiaceaePlanta medica
researchProduct

Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.

1979

The interaction of phenylbutazone with the enantiomers and racemic [ 3 H]phenprocoumon was studied in male inbred Wistar-Lewis rats following a single i.v. dose of the three forms of phenprocoumon and chronic oral treatment with phenylbutazone (average plasma concentration of about 60 Μg/ml). Phenylbutazone augmented the anticoagulant effect of R(+), S(−), and R, S (±) phenprocoumon to a similar extent. The free fraction of drug in the plasma of the enantiomers and racemic phenprocoumon increased in the presence of phenylbutazone. However, the rate of elimination of total drug from plasma and liver and the distribution between liver and plasma of all three forms of phenprocoumon remained ne…

MalePharmacologyPhenprocoumonElimination rate constantPhenylbutazonemedicineDistribution (pharmacology)AnimalsPharmacology (medical)Drug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsVolume of distributionChemistryAnticoagulantsStereoisomerism4-HydroxycoumarinsDrug interactionRatsKineticsLiverPhenylbutazoneFree fractionPhenprocoumonProthrombinEnantiomermedicine.drugJournal of pharmacokinetics and biopharmaceutics
researchProduct

Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service

2019

AbstractIn contrast to overanticoagulation, evidence on risk factors and outcome of subtherapeutic oral anticoagulation (OAC) with vitamin K-antagonists (VKAs) under optimum care is limited. We investigated the clinical phenotype, anticoagulation control, and clinical outcome of 760 VKA patients who received OAC therapy by a specialized coagulation service in the thrombEVAL study (NCT01809015). During 281,934 treatment days, 278 patients experience ≥ 1 episode of subtherapeutic anticoagulation control and had lower quality of OAC therapy compared to 482 patients without subtherapeutic international normalized ratio: 67.6%, interquartile range (IQR) 54.9%/76.8% versus 81.0%, IQR 68.5%/90.4%;…

MaleQuality Control0301 basic medicineVitaminmedicine.medical_specialtyVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyVitamin k03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolytic AgentsRecurrenceRisk FactorsInterquartile rangeInternal medicineAtrial FibrillationmedicineHumansThrombolytic TherapyInternational Normalized RatioBlood CoagulationStrokeAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelCase-control studyAnticoagulantsHematologyMiddle Agedmedicine.diseaseComorbidityPhenotypeTreatment Outcome030104 developmental biologyCoagulationchemistryCase-Control StudiesFemalebusinessFollow-Up StudiesThrombosis and Haemostasis
researchProduct

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct

Replacement therapy for bleeding episodes in factor VII deficiency: A prospective evaluation

2013

Patients with inherited factor VII (FVII) deficiency display different clinical phenotypes requiring ad hoc management. This study evaluated treatments for spontaneous and traumatic bleeding using data from the Seven Treatment Evaluation Registry (STER). One-hundred one bleeds were analysed in 75 patients (41 females; FVII coagulant activity <1-20%). Bleeds were grouped as haemarthroses (n=30), muscle/subcutaneous haematomas (n=16), epistaxis (n=12), gum bleeding (n=13), menorrhagia (n=16), central nervous system (CNS; n=9), gastrointestinal (GI; n=2) and other (n=3). Of 93 evaluable episodes, 76 were treated with recombinant, activated FVII (rFVIIa), eight with fresh frozen plasma (FFP), s…

MaleRegistrieTime FactorsFactor VII Deficiency030204 cardiovascular system & hematologyReplacement therapyProspective evaluationchemistry.chemical_compound0302 clinical medicineMedicineProspective StudiesRegistriesYoung adultProspective cohort studyFactor VII deficiencyChildHematologyFactor VIIHematologyMiddle AgedRecombinant ProteinBlood Coagulation FactorsRecombinant ProteinsTreatment OutcomeCoagulantChild PreschoolFemaleBlood Coagulation FactorHumanAdultmedicine.medical_specialtyAdolescentTime FactorHemorrhageBlood Component TransfusionFactor VIIaBleeds; Factor VII deficiency; Replacement therapy; Adolescent; Adult; Aged; Blood Coagulation Factors; Child; Child Preschool; Coagulants; Drug Administration Schedule; Factor VII Deficiency; Factor VIIa; Female; Hemorrhage; Humans; Infant; Infant Newborn; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Registries; Time Factors; Treatment Outcome; Young Adult; Blood Component Transfusion; HematologyDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineHumansAgedBleeding episodesbusiness.industryCoagulantsInfant NewbornInfantSurgeryProspective StudieTreatment evaluationchemistryBleedbusiness030215 immunology
researchProduct

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.

2010

Summary. Background: Prothrombin time (PT) and the international normalized ratio (INR) are still routinely measured in patients with liver cirrhosis to ‘assess’ their bleeding risk despite the lack of correlation with the two. Thrombin generation (TG) assays are global assays of coagulation that are showing promise in assessing bleeding and thrombosis risks. Aim: To study the relationship between the INR and TG profiles in cirrhosis-induced coagulopathy. Methods: Seventy-three patients with cirrhosis were studied. All TG parameters were compared with those from a normal control group. Contact activation was prevented using corn trypsin inhibitor. TG was also assayed in the presence of Prot…

MaleRiskmedicine.medical_specialtyPathologyCirrhosisHemorrhageGastroenterologyThrombin generationLag timeFibrinolytic AgentsInternal medicinemedicineCoagulopathyHumansIn patientInternational Normalized RatioBlood CoagulationAgedbusiness.industryThrombinAnticoagulantsHematologyBlood Coagulation DisordersMiddle Agedmedicine.diseaseThrombosisFibrosisCoagulationLiverIntercellular Signaling Peptides and ProteinsFemalebusinessPeptidesProtein Cmedicine.drugProtein CJournal of thrombosis and haemostasis : JTH
researchProduct

Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normali…

2012

Subtherapeutic international normalized ratio (INR) is frequently encountered in clinical practice, and patients with high-risk atrial fibrillation (AF) and with mechanical heart valve (MHV) with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events (TE). However, there are no prospective data evaluating this risk. Consecutive patients with a history of stable anticoagulation, but with a subtherapeutic INR, were prospectively included. Data on use and dose of low-molecular weight heparin (LMWH) bridging therapy were collected. The incidence of objectively confirmed TE and of major bleeding events within 90 days after the index INR was assessed. Five hundred…

MaleRiskmedicine.medical_specialtyPopulationvenous thromboembolismHemorrhageComorbidityThrombophiliaFollow-Up StudiePostoperative ComplicationsInternal medicineThromboembolismAtrial FibrillationmedicineHumansThrombophiliaProspective StudiesInternational Normalized RatioeducationProspective cohort studyAgedAged 80 and overHeart Valve Prosthesis Implantationeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceMedicine (all)WarfarinAnticoagulantAnticoagulantsAtrial fibrillationHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseConfidence intervalSurgeryProspective StudieHeart Valve ProsthesiHeart Valve ProsthesisFemalePostoperative ComplicationWarfarinbusinessCohort studymedicine.drugFollow-Up StudiesHuman
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study

2015

Abstract Background It is well known that atrial fibrillation (AF) and chronic kidney disease (CKD) are associated with a higher risk of stroke, and new evidence links AF to cognitive impairment, independently from an overt stroke (CI). Our aim was to investigate, assuming an underlying role of atrial microembolism, the impact of CI and CKD in elderly hospitalized patients with AF. Methods We retrospectively analyzed the data collected on elderly patients in 66 Italian hospitals, in the frame of the REPOSI project. We analyzed the clinical characteristics of patients with AF and different degrees of CI. Multivariate logistic analysis was used to explore the relationship between variables an…

MaleSettore MED/09 - Medicina InternaREPOSI studyKidneyDisability EvaluationRetrospective StudieRisk Factorshospitalized patientAtrial Fibrillation80 and overOdds RatioLS4_4Renal InsufficiencyChronicMultivariate AnalysiStrokeAged 80 and overMedicine (all)BrainAtrial fibrillationStrokeFemaleatrial microembolismHumanGlomerular Filtration Ratemedicine.medical_specialtySocio-culturaleRenal functionelderlyCognition DisorderInternal medicineThromboembolismmedicineInternal MedicineHumansRenal insufficiency chronicHeart AtriaIntensive care medicineAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; ThromboembolismAgedRetrospective Studiesbusiness.industryRisk FactorSettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studyOdds ratiomedicine.diseaseAtrial fibrillationBlood pressureHeart failureMultivariate AnalysisAged Anticoagulants Atrial fibrillation Dementia Renal insufficiency chronic Stroke.Aged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Strokeatrial microembolism; elderly; hospitalized patients; REPOSI study;DementiabusinessCognition DisordersKidney diseaseAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; Thromboembolism; Internal Medicine; Medicine (all)
researchProduct